Oncoinvent ASA (BRRGF)

Overview

BerGenBio ASA is a forward-thinking biopharmaceutical company based in Bergen, Norway, dedicated to the creation of innovative therapies for challenging medical conditions. Incorporated in 2007, the company operates at the clinical stage, focusing its efforts on the development of novel medicines aimed at treating immune-evasive, drug-resistant, and metastatic cancers, as well as certain respiratory diseases. A significant part of its mission involves tackling conditions that are currently inadequately addressed by existing treatments, with a strong emphasis on leveraging cutting-edge science to provide new options for patients worldwide. Through its commitment to research and development, BerGenBio ASA positions itself as a key player in the global effort to combat some of the most pressing healthcare challenges of our time.

Products and Services

• Bemcentinib

  An oral once-a-day inhibitor targeting the AXL receptor tyrosine kinase, bemcentinib represents BerGenBio ASA's flagship molecule. It is currently under evaluation in a range of clinical trial stages for various applications. These include a Phase 1b/2a clinical trial aimed at treating non-small cell lung cancer and a Phase 2 clinical trial focused on acute myeloid leukemia and COVID-19. Bemcentinib's versatility extends to exploratory studies in other cancers such as glioblastoma, second-line (2L) lung cancer, melanoma, pancreatic cancer, and mesothelioma, showcasing the company's ambitious approach to finding viable treatments for a wide array of challenging conditions.

• Tilvestamab

  As an anti-AXL function-blocking monoclonal antibody, tilvestamab is another innovative asset in BerGenBio ASA’s pipeline. This therapeutic is in a Phase 1b clinical trial targeting the treatment of ovarian cancer. It epitomizes the company's commitment to exploring new frontiers in cancer therapy, particularly in areas where current treatment options are limited or nonexistent.

• Mipasetamab Uzoptirine

  This candidate is in a Phase 1 clinical trial focusing on the treatment of solid tumors. Mipasetamab uzoptirine represents an integral part of BerGenBio ASA's exploration into novel therapeutic areas, highlighting its dedication to expanding the possibilities of cancer treatment and improving outcomes for patients affected by diverse types of solid tumors.

In its pursuit of innovation, BerGenBio ASA has also entered into a collaboration agreement with Merck & Co., illustrating its commitment to partnering with leading global entities to enhance the development and efficacy of its clinical trials. Such collaborations underscore the company's strategy of leveraging external expertise and resources to accelerate the path to market for its promising treatments.